MX2017000171A - Anticuerpos biespecificos anti-il4-il13. - Google Patents

Anticuerpos biespecificos anti-il4-il13.

Info

Publication number
MX2017000171A
MX2017000171A MX2017000171A MX2017000171A MX2017000171A MX 2017000171 A MX2017000171 A MX 2017000171A MX 2017000171 A MX2017000171 A MX 2017000171A MX 2017000171 A MX2017000171 A MX 2017000171A MX 2017000171 A MX2017000171 A MX 2017000171A
Authority
MX
Mexico
Prior art keywords
fragments
dual
region antibody
bispecific antibodies
binding proteins
Prior art date
Application number
MX2017000171A
Other languages
English (en)
Inventor
Esperet Corrine
Jagerschmiet Alexandre
Soubrane Christina
Subramaniam Arun
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2017000171A publication Critical patent/MX2017000171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En el presente documento se describen dosis seguras de proteínas de unión de tipo anticuerpo de doble región V o fragmentos de las mismas, así como métodos para evaluar la unión de proteínas de tipo anticuerpo de doble región y o fragmentos de las mismas a sus dianas y métodos para tratar la fibrosis pulmonar idiopática (FPI) mediante la administración de dosis seguras de proteínas de unión de tipo anticuerpo de doble región V o fragmentos de las mismas. En algunas modalidades, las proteínas de unión de tipo anticuerpo de doble región V o fragmentos de las mismas se unen tanto a la IL-4 como a la IL-13.
MX2017000171A 2014-06-27 2015-06-26 Anticuerpos biespecificos anti-il4-il13. MX2017000171A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462018253P 2014-06-27 2014-06-27
EP14306477 2014-09-24
US201562102097P 2015-01-11 2015-01-11
US201562102555P 2015-01-12 2015-01-12
PCT/IB2015/001377 WO2015198146A2 (en) 2014-06-27 2015-06-26 Anti-il4-il 13 bispecific antibodies

Publications (1)

Publication Number Publication Date
MX2017000171A true MX2017000171A (es) 2017-04-25

Family

ID=51663114

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000171A MX2017000171A (es) 2014-06-27 2015-06-26 Anticuerpos biespecificos anti-il4-il13.

Country Status (18)

Country Link
US (2) US20170145089A1 (es)
EP (1) EP3160502A2 (es)
JP (1) JP2017530089A (es)
KR (1) KR102558891B1 (es)
CN (1) CN106573975A (es)
AU (1) AU2015278829B2 (es)
BR (1) BR112016030568B8 (es)
CA (1) CA2952902C (es)
CL (1) CL2016003317A1 (es)
CR (1) CR20170022A (es)
EA (1) EA201692495A8 (es)
MX (1) MX2017000171A (es)
NZ (1) NZ728020A (es)
PH (1) PH12016502569A1 (es)
SG (2) SG10201811562YA (es)
TN (1) TN2016000569A1 (es)
TW (2) TWI745962B (es)
WO (1) WO2015198146A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
TWI745962B (zh) 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法
WO2020242989A1 (en) 2019-05-24 2020-12-03 Sanofi Methods for treating systemic sclerosis
WO2023166420A1 (en) * 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ATE119198T1 (de) 1988-04-16 1995-03-15 Celltech Ltd Verfahren zur herstellung von proteinen mittels rekombinanter dna.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US20040023338A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
CA2464695A1 (en) 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2008087194A (ja) 2006-09-29 2008-04-17 Brother Ind Ltd インクジェットプリンタ
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP5561689B2 (ja) * 2007-11-28 2014-07-30 独立行政法人理化学研究所 Ｉｌ−１７ｒｂ陽性ｎｋｔ細胞を用いたアレルギー性気道炎症及び／又は気道過敏症の治療薬のスクリーニング方法
JP5439915B2 (ja) 2009-04-09 2014-03-12 ユニマテック株式会社 硬化性含フッ素ポリエーテル組成物
CA2759848C (en) * 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
WO2011052598A1 (ja) 2009-10-26 2011-05-05 国立大学法人大阪大学 画像特徴抽出装置、画像特徴抽出方法、画像認識装置、及び画像認識方法
WO2011054893A2 (en) * 2009-11-05 2011-05-12 Novartis Ag Biomarkers predictive of progression of fibrosis
US20120156194A1 (en) 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
EP3235508B1 (en) 2011-03-16 2020-12-30 Sanofi Compositions comprising a dual v region antibody-like protein
PL3470432T3 (pl) * 2012-08-21 2022-02-07 Sanofi Biotechnology Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R
RU2698907C2 (ru) * 2012-09-07 2019-09-02 Ридженерон Фармасьютикалз, Инк. Способы лечения атопического дерматита с помощью антагониста il-4r
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
US20150225479A1 (en) 2014-02-12 2015-08-13 Sanofi Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations
TWI745962B (zh) 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法

Also Published As

Publication number Publication date
PH12016502569A1 (en) 2017-04-17
CL2016003317A1 (es) 2017-08-11
BR112016030568B1 (pt) 2023-10-17
US11136388B2 (en) 2021-10-05
US20170145089A1 (en) 2017-05-25
AU2015278829A1 (en) 2017-02-02
JP2017530089A (ja) 2017-10-12
EP3160502A2 (en) 2017-05-03
CN106573975A (zh) 2017-04-19
BR112016030568B8 (pt) 2023-12-05
TWI745962B (zh) 2021-11-11
KR102558891B1 (ko) 2023-07-21
TW201628647A (zh) 2016-08-16
CR20170022A (es) 2017-04-04
NZ728020A (en) 2022-07-01
AU2015278829B2 (en) 2021-03-25
EA201692495A8 (ru) 2017-07-31
EA201692495A1 (ru) 2017-05-31
WO2015198146A3 (en) 2016-03-31
SG11201610594WA (en) 2017-01-27
CA2952902C (en) 2024-02-13
WO2015198146A2 (en) 2015-12-30
SG10201811562YA (en) 2019-01-30
CA2952902A1 (en) 2015-12-30
KR20170020519A (ko) 2017-02-22
BR112016030568A2 (pt) 2018-02-20
TN2016000569A1 (en) 2018-04-04
TW202034954A (zh) 2020-10-01
US20190359703A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
MX2017011406A (es) Terapeuticos de anticuerpo que se unen a tim3.
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
PH12014502527B1 (en) St2 antigen binding proteins
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
PH12019500571A1 (en) Anti-pd-1 antibodies
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
NZ717399A (en) Antibodies against csf-1r
EA201892774A1 (ru) Антитела
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
PH12016502569A1 (en) Anti-il4-il13 bispecific antibodies
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
MA40164A (fr) Anticorps bispécifiques anti-il4-il13
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.